ChromaDex Corporation

7.87
-0.07 (-0.88%)
At close: Mar 18, 2025, 3:59 PM

Company Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.

The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.

It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function.

It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries.

The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

ChromaDex Corporation is headquartered in Los Angeles, California.

ChromaDex Corporation
ChromaDex Corporation logo
Country United States
IPO Date Jun 25, 2008
Industry Biotechnology
Sector Healthcare
Employees 104
CEO Frank Louis Jaksch Jr.

Contact Details

Address:
10900 Wilshire Boulevard
Los Angeles, California
United States
Website https://www.chromadex.com

Stock Details

Ticker Symbol CDXC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001386570
CUSIP Number 171077407
ISIN Number US1710774076
Employer ID 26-2940963
SIC Code 2833

Key Executives

Name Position
Michiko Kelley Chief Marketing Officer
Ozan Pamir C.F.A. Chief Financial Officer & Principal Accounting Officer
Carlos Lopez Senior Vice President & General Counsel
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory & Scientific Affairs
Frank Louis Jaksch Jr. Co-Founder & Chairman
Kendall Knysch Head of Media Relations & Partnerships

Latest SEC Filings

Date Type Title
Mar 19, 2025 8-K Current Report
Mar 10, 2025 4 Filing
Mar 04, 2025 8-K Current Report
Mar 04, 2025 10-K Annual Report
Feb 27, 2025 4 Filing
Feb 27, 2025 8-K Current Report
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing
Dec 16, 2024 8-K Current Report